进展公告 证券代码：688273 证券简称：麦澜德 公告编号：2024-068 南京麦澜德医疗科技股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司应在每个月的前 3 个交易日内公告截至上月 末的回购进展情况。现将公司回购股份进展的具体情况公告如下： 2024 年 11 月，公司未通过集中竞价交易方式回购股份。 截至 2024 年 11 月 30 日，公司通过上海证券交易所系统以集中竞价交易方式 累计回购公司股份 1,030,000 股，占公司总股本 100,000,000 股的比例为 1.03%，回 购成交的最高价为 19.99 元/股，最低价为 18.57 元/股，支付的资金总额为人民币 20,021,020.17 元（不含印花税、交易佣金等交易费用）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/2，由控股股东杨瑞嘉先生和史志怀先生提议 | | ...

Group 1: Business Overview - The company focuses on reproductive anti-aging as its second strategic product line after pelvic floor rehabilitation, with significant clinical efficacy and promotion methods [1] - The reproductive anti-aging segment has gained widespread market recognition, forming an integrated ecological chain for women's reproductive health [2] - The company provides comprehensive solutions for reproductive anti-aging needs, utilizing key technologies such as electricity, magnetism, high frequency, and focused ultrasound [2] Group 2: Target Demographics and Market Potential - The products are suitable for women in various stages post-puberty, especially those in perimenopause experiencing reproductive system decline [2] - The market for reproductive health solutions is growing annually, driven by increasing awareness and demand for improving reproductive health and alleviating menopausal symptoms [3] Group 3: Financial Performance and Challenges - The company's revenue saw a slight decline due to changes in the internal and external business environment, alongside a significant increase in R&D expenses, which accounted for approximately 17% of total revenue [4] - The decision to terminate the 2023 equity incentive plan was influenced by the company's inability to meet performance targets and significant fluctuations in stock price [4] Group 4: Sales Strategy and Market Approach - The company employs a market penetration strategy, starting with tertiary hospitals to establish regional model clients before expanding to secondary and primary hospitals, community health institutions, and clinics [5] - The sales model is primarily direct sales, supplemented by distribution for hospital markets, with a focus on building brand influence [5] Group 5: Future Developments and Risk Management - The company is committed to developing new products for women's health throughout their life cycle, with details on new products expected in the 2024 annual report [5] - The company maintains a cautious approach to investments and acquisitions, evaluating market conditions, project risks, and potential returns to mitigate investment risks [5]

证券代码：688273 证券简称：麦澜德 南京麦澜德医疗科技股份有限公司投资者关系活动记录表 （2024 年 11 月 8 日-11 月 13 日） | --- | --- | --- | --- | |----------------|-------------------------|-------------------------------------------|----------------------------------------------------------| | | R 特定对象调研 | £ 分析师会议 | | | 投资者关系活动 | £ | 媒体采访 £业绩说明会 | | | 类别 | £ | 新闻发布会 £路演活动 | | | | £ 现场参观 £其他 | | | | | | | 易方达基金、东吴医药、嘉实基金、融通基金、长信基金、安信 | | | ( | | 上海)基金、浙商证券资管、人保资产、文澜私募基金、兴银基 | | | | | 金、上海左道投资、天治基金、毅达资本、山证资管、永赢基 | | 参与单位名称 | | | 金、域秀资产、泉汐投资、重阳投资、海通资管、渤 ...

北京市中伦律师事务所 关于南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会的 本法律意见书仅就本次股东大会的召集人资格、召集和召开程序、出席本次 股东大会人员的资格、会议表决程序是否符合法律、法规、规范性文件及《公司 章程》的规定以及表决结果是否合法有效发表意见，而不对本次股东大会所审议 的议案内容以及该等议案所表述的相关事实或数据的真实性、准确性或合法性发 表意见。 本法律意见书仅供公司本次股东大会之目的使用，未经本所书面同意，不得 用作其他任何目的。 为出具本法律意见书，本所律师列席了本次股东大会，并根据有关法律、法 1 法律意见书 规、规范性文件的规定和要求，按照律师行业公认的业务标准、道德规范和勤勉 尽责精神，对公司提供的与本次股东大会有关的文件和事实进行了核查和验证。 在本所律师对公司提供的有关文件进行核查和验证的过程中，本所假设： 1. 提供给本所的文件中的所有签署、盖章及印章都是真实的，所有作为正 本提供给本所的文件都是真实、准确、完整的； 法律意见书 致：南京麦澜德医疗科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》及中国证券监 ...

证券代码：688273 证券简称：麦澜德 公告编号：2024-067 南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 11 月 13 日 （二） 股东大会召开的地点：南京市雨花台区凤展路 32 号 A2 栋北公司会议室 1、本次会议由公司董事会召集，董事长杨瑞嘉先生主持； 2、会议采用现场投票及网络投票的方式进行表决； 3、本次会议的召集、召开、表决方式符合《公司法》等有关法律、法规及本公 司《公司章程》的有关规定，会议合法有效。 （五） 公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 （一） 非累积投票议案 1、 议案名称：《关于变更公司经营范围、修订<公司章程>并办理工商登记的议 案》 审议结果：通过 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人 ...

南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会会议资料 证券代码：688273 证券简称：麦澜德 南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会会议资料 2024 年 11 月 南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会会议资料 目 录 | 2024 | 年第四次临时股东大会会议须知 | 3 | | --- | --- | --- | | 2024 | 年第四次临时股东大会会议议程 | 5 | | 2024 | 年第四次临时股东大会会议议案 | | 议案一：关于变更公司经营范围、修订《公司章程》并办理工商登记的议案...................7 南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会会议资料 南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会会议须知 为维护全体股东的合法权益，确保南京麦澜德医疗科技股份有限公司（以下 简称 "公司"）股东大会顺利进行，根据《中华人民共和国证券法》、《中华人民 共和国公司法》等法律法规及《南京麦澜德医疗科技股份有限公司章程》和公司 《股东大会议事规则》的相关规定，制定以下会议须知， ...

Group 1: Financial Performance - The company's Q3 2024 revenue reached 1.02 billion CNY, representing a year-on-year increase of 18.75% [1] - The net profit attributable to shareholders for Q3 2024 was 23.46 million CNY, a decrease of 9.39% year-on-year [1] - The net profit after deducting non-recurring items was 22.35 million CNY, showing a slight increase of 0.46% year-on-year [1] - For the first three quarters of 2024, the revenue was 3.31 billion CNY, with a year-on-year growth of 13.81% [2] - The net profit attributable to shareholders for the first three quarters was 96.07 million CNY, reflecting a year-on-year increase of 13.37% [2] - The net profit after deducting non-recurring items for the first three quarters was 88.41 million CNY, with a year-on-year growth of 22.81% [2] Group 2: Strategic Development - The company is focusing on both consumer healthcare and serious medical fields, aiming for innovation and development in pelvic floor rehabilitation [2][3] - The market for pelvic floor dysfunction (PFD) treatment is expanding, with increasing demand for clinical rehabilitation medical devices [3] - The company has launched a new intelligent diagnosis and treatment system, PI-ONE, to enhance its market position in pelvic floor rehabilitation [3] - The company plans to continue expanding into "more serious" and "more consumer" healthcare sectors to seek new growth points [3][4] Group 3: Investor Relations and Future Outlook - The company is considering stock buybacks and equity incentives to enhance shareholder value [4] - There are concerns regarding the company's ability to break through its profit bottleneck, with a focus on optimizing operations and improving efficiency [4] - The company acknowledges the competitive landscape in the consumer healthcare sector but emphasizes its commitment to innovation and maintaining a competitive edge [3][4] Group 4: Risk Warning - Any forecasts or strategic plans mentioned should not be interpreted as commitments or guarantees regarding the company's future performance [4]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京麦澜德医疗科技股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 进展公告 | 回购方案首次披露日 | 2024/7/2，由控股股东杨瑞嘉先生和史志怀先生提议 | | --- | --- | | 回购方案实施期限 | 待第二届董事会第八次会议审议通过后 12 个月 | | 预计回购金额 | 2,000 万元~4,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 103.00 | | 累计已回购股数占总股本比例 | 1.03% | | 累计已回购金额 | 万元 2,002.1020 | | 实际回购价格区间 | 18.57 元/股~19.99 元/股 | 证券代码：688273 证券简称：麦澜德 公告编号：2024-066 一、 回购股份的基本情况 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported stable revenue growth with a high growth continuation in reproductive anti-aging [1] - In Q3 2024, the company achieved revenue of approximately 102 million yuan, a year-on-year increase of 18.75%, and a net profit attributable to shareholders of 23 million yuan, a year-on-year increase of 9.39% [1] - The reproductive rehabilitation business has shown significant growth, with a revenue increase of 122% year-on-year in the first half of 2024 [1] - The company has established a wholly-owned subsidiary, Nanjing Weizhilian Medical Equipment Co., Ltd., focusing on providing comprehensive solutions for reproductive anti-aging [1][2] - The company continues to increase R&D spending, with R&D expenses in Q3 2024 amounting to 14 million yuan, accounting for 13.89% of revenue [1] Financial Summary - For the first three quarters of 2024, the company achieved revenue of 331 million yuan, a year-on-year increase of 13.81%, and a net profit of 96 million yuan, a year-on-year increase of 13.37% [1] - The projected revenues for 2024-2026 are expected to be 421 million yuan, 519 million yuan, and 639 million yuan, with year-on-year growth rates of 23.4%, 23.4%, and 23.1% respectively [2] - The projected net profits for the same period are expected to be 114 million yuan, 146 million yuan, and 184 million yuan, with corresponding year-on-year growth rates of 26.5%, 28.4%, and 26.1% [2] - The company maintains a gross profit margin of approximately 72.35% and a net profit margin of about 30.41% [1]

Financial Performance - The company's operating revenue for Q3 2024 was ¥102,193,925.70, representing an increase of 18.75% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2024 was ¥23,463,908.03, showing a decrease of 9.39% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥22,354,745.79, with a slight increase of 0.46% compared to the previous year[2] - The basic earnings per share for Q3 2024 was ¥0.2389, down by 7.19% from the same period last year[3] - Operating profit for the third quarter was CNY 113,370,138.56, up from CNY 97,638,838.14 in the previous year, reflecting a growth of 16.5%[17] - Net profit attributable to shareholders of the parent company for the third quarter was CNY 96,070,603.10, compared to CNY 84,737,526.88 in the same quarter of 2023, marking an increase of 13.7%[18] - The total comprehensive income for the third quarter was CNY 100,527,812.13, up from CNY 86,568,338.81 in the previous year, reflecting a growth of 15.9%[18] Research and Development - Research and development expenses totaled ¥15,604,342.74 for Q3 2024, an increase of 11.07% year-on-year, accounting for 15.27% of operating revenue[3] - Research and development expenses for the first three quarters were CNY 40,616,481.48, slightly down from CNY 42,856,112.93 in the same period last year, indicating a decrease of 5.2%[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,514,870,439.51, a decrease of 1.24% compared to the end of the previous year[3] - The equity attributable to shareholders at the end of the reporting period was ¥1,309,593,471.36, down by 2.69% from the previous year[3] - The company's total liabilities increased to CNY 167,379,465.15 from CNY 158,603,955.36, representing a rise of 11.2%[15] - The total equity attributable to shareholders decreased to CNY 1,309,593,471.36 from CNY 1,345,778,874.02, a decline of 2.7%[15] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥56,353,866.39, reflecting a decrease of 26.55% year-on-year[2] - The net cash flow from operating activities for the first three quarters of 2024 is CNY 56,353,866.39, a decrease of 26.4% compared to CNY 76,726,299.95 in the same period of 2023[20] - Total cash inflow from operating activities increased to CNY 353,482,030.85, up 9.2% from CNY 323,593,481.32 in the previous year[20] - Cash outflow from operating activities rose to CNY 297,128,164.46, an increase of 20.3% compared to CNY 246,867,181.37 in 2023[20] - The net cash flow from investment activities is -CNY 348,565,156.19, an improvement from -CNY 574,480,313.22 in 2023[20] - The net cash flow from financing activities is -CNY 125,598,319.37, worsening from -CNY 73,833,636.78 in 2023[21] Investments and Other Financials - The company received government subsidies amounting to ¥398,149.08 during the reporting period, contributing to its non-recurring gains[4] - The company received CNY 1,027,549,000.00 from the recovery of investments, a decrease from CNY 3,053,832,000.00 in 2023[20] - The company reported a financial income of CNY 8,129,424.10, down from CNY 11,138,245.91 in the previous year, a decrease of 26.0%[16] Shareholder Actions - The company repurchased 2,140,000 shares, representing 2.14% of its total shares outstanding as of September 30, 2024[10] Other Observations - The company has not disclosed any new product developments or market expansion strategies in the current report[11]